S&P 500   4,263.75 (+0.81%)
DOW   33,129.55 (+0.39%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
S&P 500   4,263.75 (+0.81%)
DOW   33,129.55 (+0.39%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
S&P 500   4,263.75 (+0.81%)
DOW   33,129.55 (+0.39%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
S&P 500   4,263.75 (+0.81%)
DOW   33,129.55 (+0.39%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)

Keros Therapeutics (KROS) Competitors

$30.85
0.00 (0.00%)
(As of 10/4/2023 ET)
Compare
Today's Range
$30.23
$31.06
50-Day Range
$30.82
$42.68
52-Week Range
$30.23
$59.96
Volume
102,147 shs
Average Volume
209,212 shs
Market Capitalization
$915.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$94.33

KROS vs. SLRN, ETNB, MIRM, TARS, CALT, OCS, ITOS, IDYA, ORIC, and MGTX

Should you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Acelyrin (SLRN), 89bio (ETNB), Mirum Pharmaceuticals (MIRM), Tarsus Pharmaceuticals (TARS), Calliditas Therapeutics AB (publ) (CALT), Oculis (OCS), iTeos Therapeutics (ITOS), IDEAYA Biosciences (IDYA), ORIC Pharmaceuticals (ORIC), and MeiraGTx (MGTX). These companies are all part of the "medical" sector.

Keros Therapeutics vs.

Keros Therapeutics (NASDAQ:KROS) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.

Keros Therapeutics presently has a consensus price target of $94.33, indicating a potential upside of 205.78%. Acelyrin has a consensus price target of $37.00, indicating a potential upside of 290.71%. Given Acelyrin's higher probable upside, analysts plainly believe Acelyrin is more favorable than Keros Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keros Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Acelyrin
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Acelyrin has lower revenue, but higher earnings than Keros Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keros Therapeutics$20.10M45.52-$104.68M-$4.54-6.80
AcelyrinN/AN/A-$64.77MN/AN/A

Keros Therapeutics received 26 more outperform votes than Acelyrin when rated by MarketBeat users. However, 62.50% of users gave Acelyrin an outperform vote while only 60.78% of users gave Keros Therapeutics an outperform vote.

CompanyUnderperformOutperform
Keros TherapeuticsOutperform Votes
31
60.78%
Underperform Votes
20
39.22%
AcelyrinOutperform Votes
5
62.50%
Underperform Votes
3
37.50%

Acelyrin's return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Keros TherapeuticsN/A -42.19% -38.93%
Acelyrin N/A N/A N/A

In the previous week, Keros Therapeutics and Keros Therapeutics both had 2 articles in the media. Keros Therapeutics' average media sentiment score of 1.81 beat Acelyrin's score of 0.76 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Keros Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Acelyrin
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

75.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 94.7% of Acelyrin shares are held by institutional investors. 28.0% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Keros Therapeutics and Acelyrin tied by winning 6 of the 12 factors compared between the two stocks.


Get Keros Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KROS vs. The Competition

MetricKeros TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$915.01M$5.37B$4.28B$6.30B
Dividend YieldN/A2.63%2.41%7.91%
P/E Ratio-6.804.61119.3211.96
Price / Sales45.52141.162,883.5752.39
Price / CashN/A22.5690.79105.58
Price / Book3.063.963.784.55
Net Income-$104.68M$155.63M$121.35M$181.77M
7 Day Performance-3.71%-3.60%-2.64%-2.06%
1 Month Performance-14.87%-12.47%-8.66%-9.16%
1 Year Performance-24.01%0.97%4.37%-0.79%

Keros Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLRN
Acelyrin
2.0397 of 5 stars
$9.40
-3.8%
$37.00
+293.6%
N/A$914.06MN/A0.0079Positive News
ETNB
89bio
1.96 of 5 stars
$14.40
-0.1%
$37.44
+160.0%
+160.9%$1.09BN/A-6.8245Short Interest ↓
MIRM
Mirum Pharmaceuticals
2.3872 of 5 stars
$29.77
+1.6%
$51.14
+71.8%
+37.7%$1.14B$77.06M-6.27213Analyst Report
Positive News
Gap Up
TARS
Tarsus Pharmaceuticals
2.1846 of 5 stars
$17.60
+0.9%
$46.40
+163.6%
+3.5%$574.11M$25.82M-5.2187Positive News
High Trading Volume
CALT
Calliditas Therapeutics AB (publ)
2.1096 of 5 stars
$17.14
+0.6%
$49.00
+185.9%
+14.1%$510.60M$79.63M-16.48169Positive News
OCS
Oculis
1.6389 of 5 stars
$11.34
-3.5%
$33.40
+194.5%
N/A$412.66M$960,000.000.0028Analyst Report
Gap Down
ITOS
iTeos Therapeutics
1.9306 of 5 stars
$10.54
+1.2%
$36.33
+244.7%
-44.7%$377.12M$267.63M-13.17125Analyst Revision
IDYA
IDEAYA Biosciences
2.3279 of 5 stars
$25.52
-1.2%
$32.08
+25.7%
+72.1%$1.47B$50.93M-17.60116Gap Down
ORIC
ORIC Pharmaceuticals
2.0744 of 5 stars
$5.59
-5.1%
$15.00
+168.3%
+77.5%$304.82MN/A-2.5689Positive News
MGTX
MeiraGTx
2.5013 of 5 stars
$4.56
-1.9%
$25.67
+462.9%
-44.5%$271.46M$15.92M-1.78406Positive News

Related Companies and Tools

This page (NASDAQ:KROS) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -